Menu Close

Articles on Moderna

Displaying 1 - 20 of 67 articles

Global Justice campaigners in London stand by fake coffins to highlight global COVID-19 deaths. If pharma companies waived intellectual property rights, it would be easier for low- and middle-income countries to access COVID-19 vaccines. (AP Photo/Alastair Grant)

We still need a vaccine patent waiver, but not the one on offer at the World Trade Organization meeting

Waiving patent rights on COVID-19 vaccines and drugs is still crucial to ensure access globally, but the waiver on the table at the June World Trade Organization meeting doesn’t do the job.
WHO Director-General, Dr Tedros Adhanom Ghebreyesus, during a visit at Afrigen Formulation Facilities in Cape Town, South Africa. BENOIT DOPPAGNE/BELGA MAG/AFP/GettyImages

How drug companies are sidestepping the WHO’s technology transfer hub in Africa

Moves by Moderna and BioNTech to make vaccines themselves in African countries signal that the companies aren’t considering licensing its technology to a third party for local manufacture.
Some vaccines use mRNA to make copies of the triangular red spike proteins to induce immunity. Juan Gaertner/Science Photo Library via Getty Images

How can scientists update coronavirus vaccines for omicron? A microbiologist answers 5 questions about how Moderna and Pfizer could rapidly adjust mRNA vaccines

The new omicron variant of coronavirus has a number of mutations that may require manufacturers to update vaccines. The unique attributes of mRNA vaccines make updating them fast and easy.
The Lagos State government recently approved some private health facilities to administer COVID-19 vaccines in the state. Olukayode Jaiyeola/NurPhoto via Getty Images

How the private sector can boost COVID vaccination in Nigeria

Properly engaged and monitored, Nigeria’s private sector can do more in COVID vaccination exercise.

Top contributors

More